By 2033, the United Kingdom's Cell and Gene Therapy Manufacturing Market is projected to achieve a valuation of US$ 6.5 billion, demonstrating significant growth with a compound annual growth rate (CAGR) of 23.9% during the forecast period. On the other hand, the market in Japan is expected to experience even more rapid growth, with a CAGR of 32.5% from 2023 to 2033, reaching a valuation of US$ 12.6 billion by 2033.
NEWARK, Del, June 06, 2023 (GLOBE NEWSWIRE) -- The global
Cell And Gene Therapy Manufacturing Market
is anticipated to create phenomenal growth opportunities over the forecast period by registering a CAGR of 29% from 2023 to 2033. The global market reached a valuation of around US$ 15.6 Billion in 2022 and is expected to surpass a valuation of around US$ 240 Billion by 2033. As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.
Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033. The augmenting frequency of cancer and other target diseases, combined with increasing research and development spending in pharmaceutical companies, are driving market expansion.
Get your PDF Sample Report with Latest Market In fo @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16515
Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatments that are excessively utilized to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth. In addition to that, it has been estimated that more than 50 million people will be diagnosed with cancer within the next five years.
Report Highlights:
Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.
Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.
GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.
Recent Developments:
There are approximately 1,200 cell and gene therapies in clinical trials worldwide. In the USA alone, there are around 700 investigational cell and gene therapies in clinical trials.
Various manufacturing facilities are unable to keep up with global requirements. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.
A significant portion of the viral vectors is built with adherent manufacturing, which is expensive to run. A vial of 20 million cells is likely to cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.
Ask our Market Research Expert s @ https://www.futuremarketinsights.com/ask-question/rep-gb-16515
Competitive Landscape:
The surging interest of key public and private investors in the development of advanced therapies is expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.
Key Companies Profiled :
- Thermo Fisher Scientific
- Merck KGaA
- Lonza
- Catalent Inc.
- Takara Bio Inc.
- F. Hoffmann-La Roche Ltd
- Wuxi Advanced Therapies
- Samsung Biologics
- Boehringer Ingelheim
- Novartis AG
- Hitachi Chemical Co., Ltd.
- Cellular Therapeutics
- Miltenyi Biotec
- Bluebird Bio Inc.
More Insights into th is Market :
The North American region is anticipated to dominate the global cell and gene therapy manufacturing market over the forecast period. The U.S.A. accounted for a massive proportion of the market revenues in 2022. The key driving factors for the market expansion in the country are the large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.
The United Kingdom market is expected to showcase a positive growth outlook over the evaluation period. The European region is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.
In countries like Japan, the global market is expected to propel at a CAGR of 32.5% from 2023 to 2033, surpassing a valuation of US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.
For more Report Customization, connect with us at https://www.futuremarketinsights.com/customization-available/rep-gb-16515
Market Segmentation Covered :
By Therapy Type:
-
Cell Therapy Manufacturing
- Stem Cell Therapy
- Non-Stem Cell Therapy
- Gene Therapy Manufacturing
By Scale:
- Pre-commercial/ R&D Manufacturing
- Commercial Scale Manufacturing
By Mode:
- Contract Manufacturing
- In-house Manufacturing
By Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
- Raw Material Testing
- Vector Production
- Other Workflows
By Region:
-
North America
- USA
- Canada
-
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
-
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
-
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
-
Rest of the Middle East and Africa
Interested in buying this report – now get it at a discounted price
Table of Content
(
ToC
):
1. Executive Summary | Cell and Gene Therapy Manufacturing Marke
t
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage
2.2. Market Definition
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Cell And Gene Therapy Manufacturing
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ billion)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
Request a Complete To C of this Report with figures @ https://www.futuremarketinsights.com/toc/rep-gb-16515
E xplore FMI’s related ongoing Coverage in Healthcare Market Domain :
Smart Insulin Pens Market Size The smart insulin pens market is estimated to be valued at US$ 3,927.3 million in 2023 and is expected to be valued at US$ 8,750.7 million by 2033. The adoption of smart insulin pens is likely to advance at a CAGR of 8.3% during the forecast period.
Asia Pacific Reprocessed Medical Devices Market Share The net worth of the reprocessed medical devices market in the Asia Pacific region is expected to be US$ 428.4 million in 2023. By 2033, the market is estimated to reach US$ 1,639.4 million, expanding at a CAGR of 14.4% in the meantime.
Dengue Vaccines Market Growth The dengue vaccines market will register positive growth with the overall valuation forecast to reach US$ 474.8 million in 2023. The demand for dengue vaccines is projected to surge with a projected CAGR of 12.9% by sales in volume (units).
Dental Simulator Market Opportunity The dental simulator market is expected to increase from US$ 368.8 million in 2023 to US$ 780.5 million in 2033. The dental simulator business is anticipated to capture a CAGR of 7.8% between 2023 and 2033.
Sleep Apnea Implants Market Trends : The sleep apnea implants market size is estimated to be valued at US$ 317.1 million in 2023 and is expected to reach US$ 1,158.1 million by 2033. The adoption of Sleep Apnea Implants is likely to advance at a CAGR of 13.8% during the forecast period.
Laser Therapy Devices Market Development The laser therapy devices market size is estimated to be valued at US$ 3 billion in 2023 and is expected to reach US$ 7 billion by 2033. The adoption of laser therapy devices is likely to advance at a CAGR of 8.8% during the forecast period.
DNA Polymerase Market Strategies The DNA polymerase market is likely to register positive growth with the overall valuation forecast to reach US$ 353.9 million in 2023. The demand for DNA Polymerases is projected to surge with a projected CAGR of 6.2% to reach US$ 647.5 million.
Prostate-Specific Antigen Testing Market Demand According to Future Market Insights research, during the projected period, the global prostate-specific antigen (PSA) testing market is expected to grow at a CAGR of 12.0%. The market value is projected to increase from US$ 6.3 Billion in 2023 to US$ 19.5 billion by 2033.
USA Knotless Surgical Sutures Market Outlook According to Future Market Insights research, during the projected period, the USA knotless surgical sutures market is expected to grow at a CAGR of 3.6%. The market value is projected to increase from US$ 181.0 Million in 2023 to US$ 258.7 Million by 2033.
Point-of-Care Diagnostics Market Forecast According to Future Market Insights research, during the projected period, the Global point-of-care diagnostics market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033.
Abo ut Future Market Insights (FMI):
Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.
Contact Us :
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
sales@futuremarketinsights.com
Website:
https://www.futuremarketinsights.com
LinkedIn
|
Twitter
|
Blogs
